Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Advanced Breast Cancer 2Solid Tumor, Adult 1Breast Neoplasms 1

Interventions

Fulvestrant 18Letrozole 8Anastrozole 6Capecitabine 5palbociclib 4olaparib 4Paclitaxel 4Goserelin 4Docetaxel 4pyrotinib 3exemestane 3Injections 3toripalimab 2sacituzumab govitecan 2ribociclib 2eribulin 2elacestrant 2abemaciclib 2Vinorelbine 2Trastuzumab 2FCN-437c 2Everolimus 2Dasatinib 2Aromatase Inhibitors 2Alpelisib 2Albumin-Bound Paclitaxel 2AZD9833 2vandetanib 1trastuzumab deruxtecan 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Breast Cancer × FCN-437c × Clear all
NCT06290466 2024-03-04

Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects

Ahon Pharmaceutical Co., Ltd.

Phase 1 Completed
18 enrolled
Breast

Advanced Breast Cancer

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Ahon Pharmaceutical Co., Ltd.

Phase 3 Unknown
434 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡